HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.

ABSTRACT:

Importance

Glioblastoma is an incurable tumor, and the therapeutic options for patients are limited.

Objective

To determine whether the systemic administration of HER2-specific chimeric antigen receptor (CAR)-modified virus-specific T cells (VSTs) is safe and whether these cells have antiglioblastoma activity.

Design, setting, and participants

In this open-label phase 1 dose-escalation study conducted at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital, patients with progressive HER2-positive glioblastoma were enrolled between July 25, 2011, and April 21, 2014. The duration of follow-up was 10 weeks to 29 months (median, 8 months).

Interventions

Monotherapy with autologous VSTs specific for cytomegalovirus, Epstein-Barr viru

SUBMITTER: Ahmed N 

PROVIDER: S-EPMC5747970 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature